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Abstract
Human papillomavirus (HPV) is the causative agent of human cervical cancer and has been associated with oropharyngeal
squamous cell carcinoma development. Although prophylactic vaccines have been developed, there is a need to develop
new targeted therapies for individuals affected with malignant infected lesions in these locations, which must be tested in
appropriate models. Cutaneous beta HPV types appear to be involved in skin carcinogenesis. Virus oncogenicity is partly
achieved by inactivation of retinoblastoma protein family members by the viral E7 gene. Here we show that the E7 protein
of cutaneous beta HPV5 binds pRb and promotes its degradation. In addition, we described an in vivo model of HPV-
associated disease in which artificial human skin prepared using primary keratinocytes engineered to express the E7 protein
is engrafted onto nude mice. Expression of E7 in the transplants was stably maintained for up to 6 months, inducing the
appearance of lesions that, in the case of HPV16 E7, histologically resembled human anogenital lesions caused by
oncogenic HPVs. Moreover, it was confirmed through biomarker expression analysis via immunodetection and/or
quantitative PCR from mRNA and miRNA that the 16E7-modified engrafted skin shares molecular features with human HPV-
associated pretumoral and tumoral lesions. Finally, our findings indicate a decrease of the in vitro capacity of HPV5 E7 to
reduce pRb levels in vivo, possibly explaining the phenotypical differences when compared with 16E7-grafts. Our model
seems to be a valuable platform for basic research into HPV oncogenesis and preclinical testing of HPV-associated antitumor
therapies.
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Introduction
Human papillomaviruses (HPVs) are small DNA viruses that
show strict tropism for squamous epithelium, such as cutaneous
epidermis or genital and oral mucosas. Certain HPV types are
related with human cancer of the skin, anogenital region, and
oropharynx [1–4]. The link between cervical cancer (CC), the
second most frequent cancer in women worldwide, and HPVs was
first described in 1983 by Harald zur Hausen [5]. Today there is
overwhelming evidence that certain high-risk (HR) types of
mucosal HPVs cause CC. Indeed, HPV types 16 and 18 are
responsible for around 70% of CC worldwide [6]. In recent
decades there has been a notable increase in the number of cases
detected of HPV-positive cancers of the tonsils and base of the
tongue and of oropharyngeal squamous cell carcinoma (OSCC).
Importantly, HPV-positive OSCC shows a significantly better
response to therapy than HPV-negative OSCC [7–12]. The
association between cutaneous HPV and skin cancer was first
suspected in patients with the rare inherited disease epidermodys-
plasia verruciformis (EV). These patients are highly susceptible to
infection with betapapillomavirus (betaPV) types (such as HPV5
and 8) and frequently develop keratotic skin lesions and squamous
cell carcinomas (SCC) of the skin [13,14]. In addition, the
presence of betaPV DNA in a high proportion of skin SCCs and
actinic keratoses (AK) has been observed in organ transplant
recipients (OTRs) [15] and immunocompetent individuals [16].
Moreover, the prevalence of betaPV infection in patients with
SCC exceeds 80% [17]. However, it should be mentioned that
betaPV types show a similar prevalence in normal skin and a very
low viral load in AK and SCC. Although some reports suggest that
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betaPV may play a role in the development of cutaneous SCC
[18], epidemiological studies have not clearly established a direct
link between HPV infection and non-melanoma skin cancer.
HPV infects the basal layer of the squamous epithelium, where
the viral DNA persists for many years in an episomal form [19].
The virus life cycle depends on the differentiation status of the host
cell, as mature particles are released upon epidermal desquama-
tion [4,20]. As virus replication requires the host cell’s machinery,
HPV induces the expression of host DNA replication proteins in
terminally differentiated post-mitotic cells by disrupting the strict
coupling between keratinocyte cell cycle arrest and differentiation
[21]. Cellular regulators of these processes are the retinoblastoma
protein (pRb) and the p53 tumor suppressors, which are inhibited
by the HR-HPV E7 and E6 viral oncogenes, respectively [22–24].
HPV16-derived E7 protein binds to the 3 members of the
retinoblastoma protein family: pRb, p107 and p130. Upon
interaction, these proteins are targeted for degradation [25,26],
allowing the expression of genes involved in G1-S transition,
thereby cell proliferation. Mouse models have demonstrated that
E7 is the most important HPV16 oncogene for oral and cervical
carcinogenesis, and this property is partially mediated by the
inactivation of pRb [27,28].
The molecular transforming activities of betaPVs in skin cancer
have not yet been fully characterized. Some betaPVs are thought
to act by potentiating the harmful effects of UV radiation, for
example, by impairing DNA repair and apoptosis following UV-
induced damage through E6 molecular activities [29–34].
Although the interaction between E7 proteins from betaPVs with
pRb has already been described [35,36], inhibition of the pocket
proteins has not been fully addressed for viruses such as HPV5 or
8. In addition, beta HPV38 E6 and E7 proteins are able to alter
the functions of p53 and pRb by promoting p53 phosphorylation
and stabilization, leading to the accumulation of DNp73, a potent
inhibitor of p53 transcriptional functions [36,37]. Finally, the
involvement of betaPV in skin cancer development and the
contribution of UV radiation has been confirmed in transgenic
mice such as those expressing HPV8 or HPV38 genes [8,38].
Although prophylactic vaccines developed against HR mucosal
HPVs may protect from CC development, they are not effective in
subjects who have been already infected [39]. Thus, new therapies
are needed for this population at risk of carcinoma development.
To pursue this goal, appropriate in vivo model systems are essential
to examine HPV oncogenesis, to improve existing knowledge of
cell targets and biomarkers of HPV-infected tumors, and to allow
preclinical testing of such therapies. Previously we described a
humanized animal model system based on the grafting of a human
skin equivalent in nu/nu immunodeficient mice that has been used
in clinics or for permanent skin regeneration in burn patients
[40,41]. Although the mice lack a proper immune system, the
model is able to simulate physiological processes such as wound
healing in a human context [42,43]. Our system has also proved
efficient for modeling inherited skin diseases including different
forms of epidermolysis bullosa and testing gene therapy approach-
es for these diseases [44,45].
The present study was designed to examine the molecular
activities of cutaneous beta HPV5 E7 protein in relation to the
retinoblastoma protein. Using the mouse human skin graft model,
we characterized the long-term molecular and phenotypic
consequences of E7 expression of HPV5 and HPV16. Our
findings validate the use of this model for investigating HPV-
associated diseases.
Materials and Methods
Ethics Statement
Human foreskin samples from Caucasian children donors
undergoing circumcision surgery were obtained at the blood and
tissue bank Centro Comunitario de Sangre y Tejidos de Asturias. Written
informed consent was provided by next of kin, carers or guardians
on the behalf of the donors. The use of this tissue was approved by
the ethics committee of the tissue bank. The study protocol
including the use of formalin fixed, paraffin-embedded (FFPE)
blocks of human clinical samples (cervical intraepithelial neoplasia
and bowenoid papulosis) was approved by the Review Boards of
the Hospital del Mar in Barcelona (Spain) and Hospital
Universitario 12 de Octubre in Madrid (Spain). All work was
conducted according to the principles of the Declaration of
Helsinki. Commercially available tissue microarrays (Cybrdi Inc.,
Rockville, MD, USA) were used to analyze human CC samples.
Mice were kept for the duration of the experiment in pathogen-
free conditions in individually ventilated type II cages (25 air
changes per hour) with 10 KGy-irradiated soft wood pellets as
bedding at the animal house of the CIEMAT. This institution
approved all animal experimental procedures (Approval ID#
28079-21A of the Ministerio de Medio Ambiente, Medio Rural y
Marino) according to Spanish and European directives.
E7 Plasmid Vectors and Construction of Mutants
E7 genes were cloned and fused to sequences encoding Flag
epitopes. Two complementary oligonucleotides (Supplementary
Table S1) were hybridized and cloned into the EcoRI site of
pcDNA3.1(2) (Invitrogen) containing the Flag sequence that
ended with a stop codon to obtain pcDNA3.1(2)-FLAG. E7 genes
from HPV10, HPV5 and HPV16 were obtained by PCR using
specific primers (Table S1) from plasmids pcDNA3-10E7, pBP-
5E7 and pBP-16E7, respectively. The primers allowed the cloning
into pcDNA3.1(2)-FLAG upon digestion with NotI/EcoRI (10E7)
or EcoRI (5E7 and 16E7) enzymes. Reverse primers lack the stop
codon, enabling the epitope to be inserted in-frame at the C-
terminal end of E7. Resultant E7-Flag fusions were verified by
DNA sequencing. E7 mutants lacking the LxCxE motif
(DDLYC_16E7 and DDLFC_5E7) were obtained using Quick
Change Site-Directed Mutagenesis (Stratagene). To purify the E7
proteins, we cloned E7-flagged genes into pGEX-2T (GE
Healthcare) from the corresponding pcDNA3.1(2)-E7FLAG
plasmids to obtain glutathione-S-transferase (GST)-E7-Flag pro-
teins. Thus, 10E7-Flag, 5E7-Flag and 16E7-Flag fragments were
extracted after digestion with EcoRV/PmeI and cloned into
pGEX-2T linearized with SmaI. The GST-E7-Flag genes were
sequenced to check that the fusions were properly inserted.
Retroviral transductions of 5E7-Flag and 16E7-Flag genes were
performed with the 5E7-Flag and 16E7-Flag fragments extracted
from the corresponding pcDNA3.1(2)-E7FLAG plasmids upon
digestion with PmeI, and cloned into pLZR-IRES-GFP [46]
linearized with XhoI/PmeI. Ligation clones were sequenced for
adequate insertion of E7-flagged genes in the retroviral vector.
pLZRS-E7-IRES-eGFP plasmids drive the expression of trans-
genes from the Moloney murine leukemia virus LTR sequence.
The IRES sequence located between E7 and eGFP allows
translation of both proteins from a common transcript, whereby
E7 is produced from a 59-capped mRNA and eGFP from an
IRES-dependent translation mechanism.
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GST-E7 Fusion Protein Purification and Protein
Interaction Assays
BL21 (DE3) pLysS (Promega) cells were transformed with the
pGEX-2T-derived plasmids described above. Bacterial cultures
were grown per each fusion protein. GST proteins were present in
the supernatant of cell lysates. Purification was conducted with
glutathione sepharose 4B (GE Healthcare) using the automated
system ProfiniaTM (Bio-Rad).
Protein interaction experiments were performed using cell
lysates or purified recombinant proteins. Lysates of HaCaT cells
were obtained in an extraction buffer (20 mM Tris HCl pH = 7.5,
0.6 mM EDTA, 70 mM NaCl, 0.1% NP-40 and protease
inhibitors). Purified His-pRb protein was purchased from Ozyme
(France). Briefly, GST proteins (20 mg) were incubated with
400 mg of HaCaT lysates or 0.5 mg of recombinant His-pRb in
binding buffer (20 mM Tris HCl pH = 7.5, 0.6 mM EDTA,
70 mM NaCl, 0.01% NP-40 and protease inhibitors) overnight at
4uC. Subsequently, glutathione sepharose 4B resin was added for
2 h at 4uC, after which the affinity matrix was pelleted and washed
five times with 500 ml of ice-cold binding buffer. Proteins retained
on the matrix were resolved by SDS-PAGE and transferred onto
nitrocellulose membranes for immunoblotting.
Cell Transfections, Retroviral Transductions and Artificial
Skin Preparation
The pRb-deficient human osteosarcoma Saos2 cell line was
obtained from the ATCC, and the HaCaT human skin
keratinocyte cell line was a generous gift from Dr. P Boukamp
(DKFZ Heidelberg, Germany). Cells were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS), 1% antibiotic-antimycotic mix (Gibco), and
incubated at 37uC in a humid atmosphere containing 5% CO2.
Cotransfections to analyze pRb protein levels were performed in
Saos2 cells using Fugene HD (Roche) in 10-cm dishes. Protein
levels were analyzed by immunoblotting 48 hours post-transfec-
tion. Three plasmids were used: i) 7.8 mg of either pcDNA3.1(2)-
5E7FLAG, or pcDNA3.1(2)-16E7FLAG or pcDNA3.1(2)-FLAG
(the latter, for non-E7 control ‘‘vector’’ samples); ii) 2.6 mg of
pcDNA-mycRb; and iii) 0.65 mg of pcDNA-eGFP. The ratio
Fugene HD (ml):transfected DNA (mg) that we have used is 4:1. In
experiments where increasing amounts of E7-plasmids were
compared, total cotransfected DNA was maintained constant by
adding pcDNA3.1(2)-FLAG. MG132 experiments were per-
formed by adding the inhibitor 4 hours before harvesting the
Saos2 cells. Foreskin primary human keratinocytes (PHKs) and
fibroblasts were obtained according to previously described
methods [47]. PHKs and fibroblasts were cultured as described
[47,48]. Amphotropic retroviruses were generated by transient
transfection in 293T cells as described elsewhere [46,49]. Foreskin
PHKs, seeded on lethally irradiated 3T3-fibroblast feeders, were
subjected to two rounds of infection with the retroviruses.
Proportions of eGFP-positive cells were determined by flow
cytometry (Becton Dickinson). Aliquots of the infected cells were
harvested for protein or RNA expression, or used to perform skin
grafts.
A fibrin matrix populated with fibroblasts was used as the
dermal component of the artificial skin. The fibrin matrix was
prepared according to a procedure previously described
[40,48,50]. Organotypic cultures were grown submerged until
reaching keratinocyte confluence. At this point cultures were
manually detached from the plate and placed orthotopically on the
backs of immunodeficient nu/nu mice. The grafts were about
10610 cm. In the intact xenograft, green fluorescence was readily
visualized in vivo using a fluorescence stereomicroscope under blue
light (Olympus America, Melville, NY). Successful engraftment
mice were injected intraperitoneally with 100 mg of BrdU 1 hour
before sacrifice by CO2 inhalation. The regenerated human skin
grafts were excised along with approximately 2 mm of surround-
ing mouse skin. Part of the graft was immediately snap frozen in
liquid nitrogen, another part was submerged in RNAlater for
genetic analysis, and the remainder was placed in 4% buffered
formalin or 4% paraformaldehyde, and embedded in paraffin for
hematoxylin–eosin (H&E) staining or immunostaining with
specific antibodies.
To generate bioengineered skin and graft it onto the backs of
nude mice, we performed 3 sets of retroviral infections. The overall
proportion of infected cells was 46% 610% as determined by flow
cytometry of eGFP positive cells (Fig. S1). Grafts were maintained
for 3 to 6 months to analyze the long-term phenotypic effects and
stability of viral oncogene expression. In total, four different grafts
per retroviral construct (empty vector control, HPV5 E7 and
HPV16 E7 recombinants) were performed per experiment set, and
the experiments were repeated three times thus yielding 3 sets of
12 transplants (n = 36). Two sets were maintained for about
3 months and one set for 6 months.
Gene Expression Analysis
For quantitative real-time PCR (qRT-PCR), total RNA
including miRNA was purified using the miRNAeasy Mini Kit
(Qiagen). Skin transplants were disrupted and homogenized using
MixerMill 301 (Retsch). RNA integrity was tested using Bioana-
lyzer (Agilent). For gene expression analysis, reverse transcription
was conducted with the OmniscriptH Reverse Transcription kit
(Qiagen) using oligo-dT primers. Real-time PCR was performed
using gene specific primers (Table S1) and the SYBR Green
system (Applied Biosystems). The housekeeping gene ß-glucuronidase
(GUSB) was used for normalization. TaqManH MicroRNA Assays
(Applied Biosystems) with the TaqManH Universal PCR Master
Mix reagent kit (Applied Biosystems) were used to quantify
miRNAs following the manufacturer instructions. miRNA levels
were normalized using U6B as a control small RNA. qRT-PCR
for mRNA and miRNA was performed in an ABI 7500fast Real-
Time PCR System (Applied Biosystems). Relative expression levels
were obtained by calculating ECt values (E = efficiency of PCR
amplification, Ct = cycle number at the threshold level of log-
based fluorescence) values, and normalized to the housekeeping
RNA. Normalized expression values were log2 transformed, and z-
scores were calculated (mean = 0; stdv = 1) per gene or miRNA.
Gene expression patterns of HPV-infected human samples of
cervical cancer or vulvar intraepithelial tissues were downloaded
from the Oncomine Gene Expression Signatures database [51],
and previously reported using transcriptome microarray analyses
[52,53]. As for qRT-PCR, normalized microarray expression
values were log2 transformed, and z-scores were calculated
(mean = 0; stdv = 1) for E2F1, CENPF, MELK and RFC4 genes.
Immunostaining of Paraffin Embedded Grafted Tissue
Immunohistochemistry or immunofluorescence analyses were
performed as previously reported in 5 mm thick sections after
fixation [54,55]. For immunohistochemistry, the signal was
amplified using avidin-peroxidase (ABC elite kit, Vector) and
peroxidase was visualized using diaminobenzidine as a substrate
(DAB kit, Vector). Controls were routinely performed replacing
primary antibodies with PBS (data not shown). For immunoflu-
orescence, species-specific secondary antibodies coupled to con-
venient fluorochromes (Jackson Immunoresearch) were used as
described [56]. When necessary, DAPI (Roche) was added to
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identify the nuclei. BrdU detection was done with an anti-BrdU
specific antibody. Immunofluorescence was observed using a
microscope (Zeiss Axioplan2 imaging) equipped with an epifluor-
escence source and adequate filters. Images were captured with a
digital camera (AxioCam MRm) and visualized using AxioVision
Rel.4.6 software. The CINtec Histology Kit (mtm Laboratories,
Heidelberg, Germany) was used for p16 immunohistochemistry.
The primary antibodies used are listed in Table S2.
Protein Immunoblots
Proteins were extracted from cultured cells or skin grafts after
lysis using using RIPA buffer (Trizma-HCl 50 mM, NaCl
150 mM, 0.1% SDS, 1% Triton X-100 and 0.5% deoxycholate)
supplemented with protease inhibitors. Protein concentration were
determined by the Bradford method (BioRad). Protein separation
was done using the precasted 4–12% gradient SDS-PAGE system
(Invitrogen). Proteins were transferred to nitrocellulose mem-
branes and incubated with primary antibodies. Peroxidase-
coupled secondary antibodies were detected using the Super
Signal West Pico Chemiluminescent Substrate (Pierce) following
the manufacturer recommendations. The primary antibodies used
are listed in Table S2. Protein bands were quantified using
Quantity One software (Bio-Rad).
Results
Cutaneous HPV5 E7 Protein Reduces pRb Protein Levels
The transforming activities of the E7 oncogenes of HR-HPVs
are mainly attributable to their ability to inhibit pocket proteins by
reducing their protein levels. To confirm such activity in HPV5 E7
protein, cotransfection experiments were conducted using plas-
mids expressing E7-Flag and pRb genes in the pRb-deficient
Saos2 human osteosarcoma cell line. Also, we cotransfected an
eGFP-expressing plasmid as a control of transfection efficiency.
Our results show a clear decrease in pRb protein levels upon
transfection with HPV16 E7 (16E7) (Fig. 1A), as reported
elsewhere [26]. Interestingly, the E7 protein from HPV5 shows
a similar effect (Fig. 1A). As a negative control, E7 from HPV10
did not produce such a reduction, as already described [36].
Retinoblastoma protein reduction was more efficient when
increasing amounts of the cotransfected E7-plasmids were used,
both for HPV5 E7 and for HPV16 E7 (Fig. 1B). This confirms the
reduction is dependent on E7-dose. The E7 effect on pRb levels
could require direct binding. Using purified GST-E7-Flag proteins
(Fig. S2A and B), we showed that E7 from HPV5 (as well as
HPV10 and 16) is able to interact with pRb in vitro using lysates
obtained from the human skin HaCaT cell line (Fig. S2C) or
purified His-pRb (Fig. S2D), as has been described [22,57,58].
Mutational analyses indicate that the LxCxE motif of the N-
terminal domain of HPV16 E7 protein is necessary for binding to
pocket proteins. Using the Saos2 cotransfection system and E7
mutants (Materials and Methods), we confirmed that the capacity
of the cutaneous E7 protein to reduce pRb levels by HPV5 E7 was
dependent on an intact LxCxE motif, similarly to the HPV16 E7
protein (Fig. 1C), linking the binding ability with the effect on
retinoblastoma protein levels.
HR-HPV E7 proteins decrease pRb levels by driving their
degradation through the proteasome pathway. Using the Saos2
cotransfection system, we showed that steady-state pocket protein
levels increase with MG132 concentrations, both for HPV5 E7
and HPV16 E7, indicating that HPV5 E7 might induce pRb
destabilization through the proteasome, in a manner similar to
HPV16 E7 (Fig. 1D).
Overall, these results indicate that expression of the HPV5 E7
protein induces pRb reduction, and that this reduction is at least in
part mediated by proteasome-mediated degradation.
E7-transduced Human Skin Grafts Display Stable
Transgene Expression
In order to test the feasibility of our human skin grafting model
for HPV analysis, we expressed the E7 genes from HPV5 and 16
by retroviral transduction of foreskin PHK cells to generate
bioengineered skin, which was afterward transplanted onto the
back of nude mice (see Materials and Methods). The added value
of this approach is the grafting time, since the skin can be
maintained for months on the animals. Thus, the long-term effect
of HPV16 E7 expression in a properly assembled, mature human
skin can now be analyzed in vivo. Moreover, the transgene
expression from the retroviral construct may be easily monitored
with eGFP as the E7 and eGFP genes are translated from the same
mRNA transcript by the insertion of an IRES sequence between
both open reading frames (see Materials and Methods).
Prior to grafting, PHKs infected with E7-coding retroviruses
expressed the E7 and eGFP transcripts as demonstrated by qRT-
PCR (Fig. S3A). The expression of E7 proteins in PHKs also
promoted the reduction in endogenous pRb, p107 and p130
protein levels (Fig. 1E), but not in their corresponding transcripts,
as determined by qRT-PCR (Fig. S4). However, the existence of
residual pocket protein expression is explained because not all
infected PHKs were successfully transduced (Materials and
Methods, Fig. S1). In agreement with the reduction in pocket
proteins, augmented expression of proliferation markers PCNA
and cyclin A was detected. We also observed a slight increase in
p53 expression, concomitant with the increase in the proapoptotic
Bax protein and the cell cycle inhibitor p21, both directly
regulated by p53. However, no increase was observed in p16,
another cell cycle inhibitor normally overexpressed in HR-HPV-
infected human biopsy specimens, suggesting that E7 alone might
not deregulate p16 in human PHKs. In summary, PHKs
transduced with HPV5 E7 share molecular features with
oncogenic 16E7.
The E7-transduced PHK cells were used to generate bioengi-
neered skin and subsequent grafting. Overall, 29 out of 36
transplants could be maintained until the end of the grafting time,
indicating a high percentage of grafting success (80%) (Table 1)
(Materials and Methods). EGFP expression was monitored by
qRT-PCR (Fig. S3A), by green fluorescence visualized in the
intact xenografts (Fig. S3B and C), and by immunostaining with a
specific anti-eGFP antibody (Fig. S5). The patched immunostain-
ing pattern of eGFP may be explained because grafting was
performed with the pool of infected PHKs, containing both eGFP-
positive (truly transduced) and negative cells. In all cases, E7
expression was also monitored by qRT-PCR (Fig. S3A). Overall,
the transplants expressed the E7 genes at the time of collection,
demonstrating that the humanized mouse model is able to unveil
the long-term effects of HPV oncogenes.
E7-modified Engrafted Human Skin Shows Histological
Features Compatible with HPV-associated Lesions
Through dermatoscopic visualization, macroscopic alterations
could be identified in HPV16 E7-grafts as compared to controls.
These alterations included epidermal thickening and desquama-
tion, probably associated with hyperkeratosis (Fig. S6), which were
not observed in HPV5-grafts. Moreover, HPV16 E7 samples also
displayed papillomatous structures with capillaries and crypts
(Fig. S6). These macroscopic features resemble those of human
A Humanized Mouse Model of HPV-Pathologies
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viral warts. Histological analysis of the transplants confirmed these
observations, and showed that the HPV16 E7 gene induced
phenotypic changes when compared with control grafts (Fig. 2 and
Table 1). Most HPV16 E7 samples showed acanthosis associated
with hyperplasia, suprabasal mitotic figures, hyperkeratosis,
parakeratosis, hypergranulosis, nuclear atypia, papillomatosis
and capillaries (Fig. 2C–F). No significant histopatological
differences were observed between 5E7 and control vector grafts
(Fig. 2A and B). Since similar features are present in cervical
intraepithelial neoplasia (CIN) [59] (Fig. 2G), cervical carcinoma
(CC), bowenoid papulosis (BP) lesions (Fig. 2H–J), vulvar
intrapitelial neoplasia (VIN) or wart-like lesions [60], we demon-
Figure 1. Cutaneous HPV5 E7 protein reduces pocket proteins levels. (A) Immunoblots of Saos2 lysates cotransfected with either
pcDNA3.1(2)-FLAG (Vector), pcDNA3.1(2)-10E7FLAG (10E7), pcDNA3.1(2)-5E7FLAG (5E7), or pcDNA3.1(2)-16E7FLAG (16E7) plasmids. The effect
on pRb expression levels was tested upon cotransfection with the pcDNA-mycRb vector in all cases. Transfection efficiencies were assesed using
pcDNA-eGFP. Note that both 5E7 and 16E7, but not 10E7, induced a significant decrease in transiently expressed pRb protein. (B) Immunoblots of
Saos2 lysates cotransfected with pcDNA3.1(2)-FLAG (Vector) or with increasing amounts of either pcDNA3.1(2)-5E7FLAG (5E7) or pcDNA3.1(2)-
16E7FLAG (16E7) plasmids in the presence of similar amounts of pcDNA-mycRb. Lower panel shows the relative quantification of pRb with respect to
eGFP. Note that both 5E7 and 16E7 reduced pRb levels in a dose-dependent manner. (C) Immunoblots of Saos2 lysates cotransfected with either
pcDNA3.1(2)-FLAG (Vector), pcDNA3.1(2)-5E7FLAG (5E7), pcDNA3.1(2)-DDLFC_5E7FLAG (mut_5E7) pcDNA3.1(2)-DDLYC_16E7FLAG
(mut_16E7) or pcDNA3.1(2)-16E7FLAG (16E7) plasmids in the presence of pcDNA-mycRb. (D) Immunoblots of Saos2 lysates cotransfected with
either pcDNA3.1(2)-FLAG (Vector), pcDNA3.1(2)-5E7FLAG (5E7) or pcDNA3.1(2)-16E7FLAG (16E7) plasmids in the presence of pcDNA-mycRb and
increasing concentrations of the proteasome inhibitor MG132. Lower panel shows the relative quantification of pRb with respect to eGFP. Note that
MG132 inhibits pRb reduction mediated by 5E7 and 16E7. (E) Foreskin PHK cells were infected with retroviruses generated by pLZRS-E7-IRES-GFP
vectors. Immunoblots prepared using specific antibodies showed reduced protein levels of pRb, p107 and p130 upon transduction with E7 from both
HPV5 and 16. 5E7 was visualized with an anti-FLAG antibody, and 16E7 with an anti-16E7 antibody. E7 induced the expression of proliferation markers
(PCNA and cyclin A), tumor suppressor p53, the proapoptotic effector Bax and the cell cycle inhibitor p21. No increase in the cell cycle inhibitor p16
was observed.
doi:10.1371/journal.pone.0041743.g001
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Figure 2. Histopathology of E7-grafts and human HPV-infected pathology samples. H&E staining of representative samples of control
vector, HPV5 E7 and HPV16 E7 transplants [Skin grafts: upper images (A to F)], as well as CIN1 and bowenoid papulosis (BP) human HR-HPV-
infected samples [Human pathology samples: lower images (G to J)]. The histology of vector and 5E7 samples is similar to that of normal skin,
with basal, spinous, granulous and cornified layers properly assembled in a mature, differentiated squamous epidermal epithelium of normal
thickness (A and B). All 16E7-grafts display epidermal acanthosis (C). Features observed in human HR-HPV-infected lesions are present in HPV16 E7-
grafts including suprabasal mitosis (white arrows in D), nuclear atypia (black arrowheads in D, G and H), hyperkeratosis (black circles in C, E, F, and J),
parakeratosis (black arrows in E and I), papillomatosis (F), hypergranulosis (asterisks in C and D) and capillaries (white arrowheads in F and J).
doi:10.1371/journal.pone.0041743.g002
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strated that 16E7-expressing, reconstituted human bioengineered
skin transplanted onto nude mice, could constitute a faithful model
of HPV-pathobiology.
Epithelial Differentiation and Proliferation in Engrafted
Skin
To confirm our histology findings, suggestive of abnormal
differentiation, we then explored the expression of epidermal
differentiation markers by immunofluorescence. Cytokeratin K5, a
marker of basal cells, showed a normal pattern in all the
transplants (Fig. 3A–C, D–F), although K5-positive cells could
eventually be seen in suprabasal layers in HPV16 E7-samples
(Fig. 3J and K). Remarkably, these cells also exhibited the
expression of cytokeratin K10 (early differentiation marker)
(Fig. 3J) or involucrin (late differentiation marker) (Fig. 3K),
revealing the known ability of HPV16 E7 expression to uncouple
proliferation and differentiation processes. Normal suprabasal K10
expression was observed in all cases (Fig. 3D–F), but areas of
reduced expression could be seen in HPV16 E7-transplants
(Fig. 3F). Finally, involucrin expression was normally confined to
the uppermost layers of spinous cells and the granulous layer in
controls (Fig. 3A), whereas an expansion of involucrin expression
was observed in the HPV16 E7-transplants (Fig. 3C), in agreement
with the observed thickening of highly differentiated cell layers. No
major changes were observed in HPV5 E7-transplants (Fig. 3B).
The hyperplasic phenotype observed in HPV16 E7 engrafted
skin suggested augmented cell proliferation. This was further
demonstrated by BrdU incorporation and PCNA expression in
basal and suprabasal cells (Fig. 3F, I–K) compared to controls
(Fig. 3D and G), that reached the upper layers of the grafted
human skin. These findings support HPV16 E7 expression
uncoupling proliferation and differentiation processes. In contrast,
ectopic suprabasal proliferation was only detected in focal areas of
the HPV5 E7-transplants (Fig. 3E and H). The HR-HPV E7
expression induces the expression of cell cycle regulators p21 and
cyclin A in organotypic cultures and in pathological HPV-infected
samples [61–63]. Through immunohistochemistry, we confirmed
the virtually absent expression of both proteins in the bioengi-
neered vector transplants (Fig. 4A and D). However, expression
was focally observed in HPV5 E7-samples (Fig. 4B and E) or
throughout HPV16 E7-grafts (Fig. 4C and F), being more evident
for p21. The augmented expression of PCNA, p21 and cyclin A
proteins was also observed in PHKs soon after retroviral infection,
before transplantation (see above, Fig. 1E).
These results indicate that histological features reflecting
increased proliferation (acanthosis or suprabasal mitosis) are
associated with the induction of proliferation markers and cell
cycle regulators in the case of 16E7. Grafts expressing E7 from
HPV5 did not display evident histological changes (see above,
Fig. 2 and Table 1), but deregulation of such proteins could be
eventually observed. In line with this finding, the overexpression of
p21 determined at the mRNA level was only significant in
the16E7 transplants (Fig. S7), pointing to the incomplete activity
of 5E7 in PHKs upon grafting.
Apoptosis in E7-engrafted Skin
The HPV16 E7 protein stabilizes the p53 tumor suppressor and
induces apoptosis in cultured cells [24]. In agreement, we found
that the E7-transduced PHKs prior to grafting show moderately
increased expression of p53 and Bax, which is a proapoptotic
inducer directly regulated by p53 (see above, Fig. 1E). However,
we wanted to determine apoptosis in skin grafts using both p53
and active caspase-3, a processed protein which signals both
extrinsic (death ligand) and intrinsic (mitochondrial) apoptotic
pathways [64]. The results indicated no significant programmed
cell death in control vector (Fig. 5A) or in the E7-transplants
(Fig. 5B and C), although some few p53 or active caspase-3
positive cells appeared in HPV16 E7 grafts (Fig. 5D). In
conclusion, E7 expression in the transplants appears to induce
no substantial cell death. However, as caspase-3 is cleaved by HR-
HPV-infection upon epithelial differentiation to induce viral
genome amplification [65], we cannot discard that caspase-3
positive cells are non-apoptotic cells.
Differential Activities of E7 Proteins from HPV5 and 16 in
Skin Grafts
Histological and molecular characterization of the skin grafts
demonstrated differences between the phenotypic effects of the
expression of cutaneous HPV5 E7 and mucosal HPV16 E7,
despite the similarities observed in vitro using transfected Saos2
cells and transduced foreskin PHKs in culture (see above, Fig. 1).
Immunohistochemical markers of proliferation and cell cycle
regulators revealed an ectopic suprabasal expression in patches of
the 5E7-grafts, while the effect was mostly general in the 16E7-
gratfs. A possible explanation is that the LTR regulatory sequences
might be silenced by epigenetic mechanisms in the case of 5E7-
grafts. Detection of 5E7 protein expression by immunohistochem-
istry was not possible as the anti-Flag antibodies produced no
specific signal. However, i) qRT-PCR of 5E7 and eGFP genes, ii)
green fluorescence visualization of intact xenografts, and iii) eGFP
immunohistochemistry (Fig. S3 and S5) indicated active transgene
expression. This findings, together with absence of apoptosis (see
above, Fig. 5), discarded a negative selection of HPV5 E7-
transduced cells during grafting time. An alternative explanation is
that HPV5 E7 cannot target pocket proteins with a similar
efficiency as that observed in vitro. We tested this hypothesis by
obtaining protein lysates from the skin grafts, and analyzing the
expression of the pocket proteins (Fig. 6A). We also determined
their expression relative to eGFP, which is translated from the
same transcript as E7 in order to normalize differences due to
variability between grafts (Fig. 6B). Interestingly, results showed
that pRb expression is significantly reduced in 16E7-transplants, in
agreement with the increased expression of proliferation markers.
However, pRb levels were not significantly modified in skin grafts
with the HPV5 E7 gene. No significant differences were observed
in p107 and p130 expression for both 5E7 and 16E7 samples. In
view of these results, we suggest that the absence of a phenotype
for the cutaneous E7 gene might be the lack of effective pRb
reduction that occurred in vivo.
Validation of the E7-grafts as a Model for HPV-associated
Disease
To validate our humanized mouse model of HPV-pathology
analyses, we examined the expression of several biomarkers
previously identified as surrogate markers of HPV infection in
pathology samples. The cellular protein MCM7, a helicase
involved in DNA replication, is induced by HPV-E7 expression
in clinical samples of CIN and carcinoma lesions [66]. Immuno-
histochemistry indicated MCM7 expression in basal cells of
control vector samples (as expected) (Fig. 7A). Ectopic suprabasal
expression was focally observed in HPV5 E7 grafts (Fig. 7B) (as for
PCNA, p21 and cyclin A, see above Fig. 3 and 4). In contrast,
MCM7 displayed continuous ectopic suprabasal expression in
HPV16 samples that reached the uppermost spinous cells (Fig. 7C–
C’’’).
Further, 16E7-grafts and clinical samples of mucosal HR-HPV-
associated lesions (CIN, CC and BP) were compared by
A Humanized Mouse Model of HPV-Pathologies
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immunohistochemistry, both for MCM7 and PCNA. Results
revealed similar staining patterns for both proteins in the 16E7-
grafts (Fig. 8A) and all the pathological cases (Fig. 8B–D, Fig. S8B
and C). PCNA and MCM7 were ectopically expressed in the lower
epithelial suprabasal layers of CIN1, and their expression
expanded upwards in CIN3 (Fig. 8C, Fig. S8B), reaching almost
all tumor cells in CC samples (Fig. 8B), as described elsewhere.
Similar p16 staining patterns were produced in the CC or CIN
Figure 3. Epidermal differentiation and proliferation markers in E7-grafts. Sections of paraffin-embedded grafts were processed for
immunofluorescence staining with antibodies to epithelial differentiation markers (basal cytokeratin 5, early suprabasal cytokeratin 1 and 10, and late
suprabasal involucrin) and proliferation markers (BrdU, PCNA). As in normal skin, cytokeratin 5 (K5) is expressed in the basal layer, cytokeratin 10 (K10)
and 1 (K1) in early suprabasal cells, and involucrin (Inv) in late differentiated cells in control vector samples (A, D and G). A similar phenotype was
observed in the HPV5 E7 samples (B, E and H). An expansion of involucrin positive cells downwards was observed in HPV16 E7-transplants (C and K).
BrdU and PCNA, normally present in some basal cells (D and G), are ectopically present in suprabasal cells of HPV16 E7 samples (F and I). Focal areas
of suprabasal PCNA positive cells occur in HPV5 E7 samples (H). Importantly, suprabasal K5/K10 positive (J) or K5/involucrin positive cells (K) were
observed in 16E7-grafts. Where indicated, DAPI staining was used to visualize cellular nuclei. K5Inv: staining with both K5 and involucrin antibodies;
K5K10BrdU: staining with K5, K10 and BrdU antibodies; K1PCNADAPI: staining with K1, PCNA and DAPI. Dashed line indicates the location of the
basal membrane.
doi:10.1371/journal.pone.0041743.g003
A Humanized Mouse Model of HPV-Pathologies
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samples (Fig. 8B and C). However, we could not observe
differences in p16 expression between control and E7-grafts, by
immunohistochemistry on skin grafts (Fig. S8A) or by immuno-
blots in PHKs (see above, Fig. 1E). Importantly, PCNA and
MCM7 show a strong pattern similarity with BP human samples,
where both proteins are expressed in most suprabasal cells (Fig. 8D,
Fig. S8C). Moreover, close inspection showed that not all basal
cells exhibited MCM7, PCNA or p16 expression in CIN1 (Fig. 8C)
or BP (inserts in Fig. 9D), as occurs in 16E7 grafts (Fig. 7C–C’’’
and Fig. 8A). However, CIN3, CC and high grade BP did express
both markers in all basal cells (Fig. 8B and C, Fig. S8B and C),
pointing to a clonal selection of malignant infected cells in the
basal layer during tumor progression.
We recently reported a meta-analysis of expression profiling
experiments performed on HR-HPV infected human samples
[67]. The overexpression was described of genes involved in DNA
replication and proliferation such as E2F transcription factor 1
(E2F1), centromere protein F (CENPF), maternal embryonic leucine zipper
kinase (MELK) and replication factor C (activator 1) 4 (RFC4) in
various independent microarray studies performed on HPV-
infected CC and head and neck squamous cell carcinomas
(HNSCC). The expression of these genes was slightly induced in
PHKs expressing E7 genes prior to grafting (Fig. 9A). In contrast,
E2F1 is significantly overexpressed by both E7 genes in grafts
(Fig. 9A). Furthermore, CENPF, MELK and RFC4 genes are
overexpressed in HPV16 E7 expressing grafts (Fig. 9A). The
Figure 4. Induction of p21 and cyclin A in E7-grafts. Sections of paraffin-embedded grafts were processed for immunohistochemistry staining
with antibodies to cell cycle inhibitor p21 and cell cycle regulator cyclin A. With respect to control vector grafts (A and D), both p21 and cyclin A
proteins are induced in suprabasal cells of HPV16 E7 transplants (C and F) and in focal HPV5 E7 areas (B and E). In the inserts, dotted lines indicate the
location of the basal membrane.
doi:10.1371/journal.pone.0041743.g004
A Humanized Mouse Model of HPV-Pathologies
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expression patterns of these 4 genes in HR-HPV-infected VIN
[53] and CC samples [52] (compared to their respective normal
control tissues) are provided to demonstrate their similar
deregulation trends (Fig. 9B).
MicroRNAs (miRNAs) are endogenous small non-coding RNAs
capable of modulating gene expression by post transcriptional
mechanisms. miRNAs are involved in numerous of normal or
pathological cell processes, such as cancer. In HPV-infected CC or
HNSCC, miR-145, miR-146a, miR-148a, miR-200a, miR-203
and miR-21 (among others) are deregulated, some of them in
association with clinical variables [10,68–71]. Thus, through qRT-
PCR we examined the expression of these specific miRNAs in
grafts. No expression differences were observed in the expression
of miR-148a, miR-145 or miR-203 when compared to control
vector grafts (Fig. S9). However, we found significant overexpres-
sion of miR-146a and miR-200a in HPV16 E7-grafts, and miR-21
in both HPV5 E7- and HPV16 E7-grafts (Fig. 9C).
Collectively, these observations indicate that the 5E7-grafts,
despite the similarity with normal vector skin at the histology level,
display a slight deregulation of HPV-biomarkers. In addition,
16E7-transplants exhibits molecular deregulation of HPV-infected
carcinomas and support the idea that our model is able to
recapitulates molecular the features that characterize HPV-
associated pathologies.
Figure 5. E7-grafts showed no significant apoptosis. Sections of paraffin-embedded grafts were processed for immunofluorescence staining
with antibodies to the apoptosis markers caspase-3 active and p53. Caspase-3 active is not expressed in control vector samples (A), but some
scattered positive cells are observed in HPV5 E7 (B) and HPV16 E7 grafts (C and D). No p53 staining was observed in control and HPV5 E7 samples
(not shown), but eventual, p53-positive cells were observed in the HPV16 E7-transplants (D). Dotted line indicates the location of the basal
membrane. Inserts in panels B–D show magnified areas of staining. DAPI was used to visualize cell nuclei.
doi:10.1371/journal.pone.0041743.g005
A Humanized Mouse Model of HPV-Pathologies
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Discussion
The findings of our study indicate that HPV5 E7 is able to
reduce pRb levels in vitro, in a manner that is most likely
dependent on protein destabilization. Also, we adapted our
previously described humanized murine model to analyze the
long-term in vivo phenotypic consequences of E7 (from HPV5 and
HPV16) expression. To validate the model, the functionality of
transduced 16E7 was supported by expected E7 protein activity
and alterations in epithelial homeostasis, histopathology, and
biomarkers of HPV-associated neoplasia. The model emerges as a
valid tool for dissecting the molecular pathogenesis of HPV as well
as for pre-clinical testing of therapies for HPV-associated
malignancy.
A major feature of our humanized model is the long-term
stability of the transgene expression. Two sets of transplants were
maintained for up to 3 months after engrafting, and one set was
kept longer, for 6 months. No significant differences were observed
between both transplant durations in terms of phenotype
aggravation, transgene (E7 and eGFP) expression/silencing, or
biomarker induction. Thus, unlike the situation with (non-
engrafted) organotypic skin, pathogenesis could be analyzed
during prolonged time periods (minimum of 6 months), which
may allow for a more physiological analysis of E7 functions, and
more adequate tests of toxicity and efficiency for new possible
therapies. Although transgenic mice expressing HPV oncogenes
represent good organism model systems, they might not fully
recapitulate the human histopathology and molecular interactions
due to possible intrinsic differences between humans and mice.
Compared with transgenic mice, in the humanized model the
consequences of E7 expression could be analyzed using human
primary keratinocytes, as the true targets of HPV infection.
Although the absence of a normal immunological system in nu/nu
mice could be considered a disadvantage of the model, is worth
considering that immunosuppression is likely to contribute to the
malignant development of HPV-associated lesions. It is true,
however, that this model is not useful to address antitumor
therapies based on immune system interactions or induction.
The HPV16 E7 grafts established here showed histopathological
and/or molecular features that can be observed in HPV-associated
BP, VIN, wart-like lesions, CIN or CC. Of note, the augmented
proliferation of basal and suprabasal cells, the disorganized
differentiation, and the ectopic expression of p21 and cyclin A,
are in line with previous findings in organotypic cultures and
HPV-based transgenic mice, thus validating our model. In human
clinical samples, immunostaining revealed that MCM7 and PCNA
are restricted to the basal and/or early suprabasal cells in low
grade CIN but are also overexpressed in the upper layers of the
epithelia in high-grade CIN lesions, CC, and BP. Remarkably,
grafts obtained upon expression of HPV16 E7 were found to
express MCM7 and PCNA in all suprabasal layers up to the
spinous cells of the skin epidermis, thus resembling high grade
CIN lesions, CC and BP. However, patched expression in basal
cells was observed in 16E7-grafts (Figures 7 and 8A), which may be
a consequence of the coexistence of transduced and non-
transduced cells. As basal cells expressing E7 displayed prolifer-
ative potential over E7-negative cells, they expanded upwards
more efficiently while expressing MCM7 and PCNA in differen-
tiated cells. Importantly, similar findings were observed in CIN1
Figure 6. Pocket proteins expression in skin grafts. (A) Pocket protein and eGFP expression was analyzed by immunoblotting with specific
antibodies using graft protein lysates from control vector, 5E7 and 16E7 samples. (B) Pocket protein and eGFP protein expression bands were
quantified and relative (pocket protein/eGFP) values plotted. Horizontal green lines represents mean relative values. According to Student’s t-test,
significant differences were only detected in pRb/eGFP expression values between vector and 16E7 samples (threshold p-val,0.05). *: p-val,0.05.
doi:10.1371/journal.pone.0041743.g006
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and bowenoid papulosis samples, where positive and negative
basal cells coexisted in the lesions (Fig. 8C and D).
The absence of p16 expression in 16E7-grafts is the major
difference with HR-HPV-infected human pathological samples.
Normally, p16 is expressed in CIN, CC and BP associated with the
infection of oncogenic mucosal HPVs (mostly HPV16 and 18).
Our results suggest that additional oncogenic events might be
needed to induce ectopic expression of p16 in human lesions, such
as co-expression with other viral genes (such as E6) and/or
mutational events within the human genome. Further analysis
must be performed to determine the molecular mechanisms by
which p16 is induced HR-HPV-infected human samples.
Our biomarker characterization of the grafts revealed the
induction genes such as E2F1, CENPF, MELK and RFC4, or
miRNAs such as miR-21, miR-146a and miR-200a. Importantly,
miR-21, which displays oncogenic and metastatic activity [72], is
also overexpressed in cell lines and clinical samples of HNSCC
[12] and CC [68,69] and is associated with a poorer prognosis
Figure 7. HPV surrogate marker MCM7 is ectopically expressed in E7-transplants. Sections of paraffin-embedded grafts were processed
for immunofluorescence staining with antibodies to MCM7. MCM7 is normally confined to the basal layer as in control vector transplants (A).
Suprabasal expression is eventually observed in HPV5 E7-samples (B). Importantly, MCM7 is expressed in HPV16 E7-grafts in most suprabasal cells,
reaching the uppermost spinous cells. Representative images of different 16E7-grafts are shown (C, C’, C’’, C’’’).
doi:10.1371/journal.pone.0041743.g007
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Figure 8. Similarities between 16E7-grafts and HPV-infected anogenital neoplasias identified by immunohistochemistry. (A) Both
PCNA and MCM7 displayed similar ectopic expression in most suprabasal cells of 16E7-grafts. In the basal layer, areas of expression coexisted with
expression-free areas. (B) The same patterns were observed in tumor areas of cervical carcinoma samples where p16 was also present. PCNA and
MCM7 expression expands progressively upwards in CIN1 and CIN3 (C), while most basal and subrabasal cells were stained in different cases of
bowenoid papulosis (D). Middle panels in C and inserts in D highlight areas of basal cells showing negative staining for MCM7, PCNA and p16 (the
latter, in CIN1). Dotted lines indicate the location of the basal membrane.
doi:10.1371/journal.pone.0041743.g008
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[73]. Although the possible mechanism of miR-21 induction by E7
in grafts is not known, the model can be used to analyze the in vivo
consequences of miR-21 inhibition by pharmacological or genetic
approaches. miR-146a expression is regulated by NF-kB signaling
[74] and, accordingly, changes in miR-146a expression have been
described not only in CC and other cancers [68,69], but also in
psoriasis and in skin inflammatory processes [75]. Consequently,
the upregulation of miR-146a could potentially inhibit the
activation of inflammation upon in vivo infection, thus contributing
to the progression of asymptomatic HPV-associated pathology.
Finally, we detected the overexpression of miR-200a in the
HPV16 E7-grafts. Since miR-200a negatively regulates epithelial
to mesenchymal transition [7,76], its increased expression is in line
with the lack of invasive properties of the HPV16E7-grafts.
The histology and molecular differences between 5E7 and
16E7-grafts could be partially explained by ineffective degradation
of 5E7 over pRb. We are tempting to speculate that human skin
SCC infected with HPV5 might need additional cellular mutations
that could cooperate with virus-induced transformation, such as
those produce by UV irradiation. Further experiments using UV
irradiation may corroborate such hypothesis. In this sense, K14-
HPV38 transgenic mice develop tumors upon chemical or UV
stimuli [8]. However, we cannot discard that the cutaneous virus
protein lacks other molecular activities that the HR-HPV16 E7
protein displays, such as inhibition of p21 function [77–79].
Whether p21 is active or not in the HPV5 E7-grafts remain to be
ascertained, although protein expression was only observed in
patched areas.
In summary, we present a new model system to analyze the
functions of the HPV oncogenes in human keratinocytes that can
be maintained for several months. This model represents a new
in vivo tool, which could be combined with analyses in monolayer
cell culture and organ systems for preclinical validation of
therapies against HPV-diseases. The validity of the model is
supported by our histopathological findings and the expression of
several biomarkers of HPV infection and carcinogenesis. Addi-
tional experiments analyzing the cooperative roles of both E6 and
E7 proteins merits further investigation, as both oncogenes are
expressed in human tumor samples. We propose this model may
be useful for preclinical tests designed to search out new efficient
molecularly targeted therapies against HPV-associated lesions.
Supporting Information
Figure S1 Infection efficiency of E7-containing retrovi-
ral vectors in foreskin PHKs. A) A representative example of
a flow cytometer analysis is shown in which the percentage of
PHK cells is plotted against eGFP fluorescence. B) Table shows
the percentage of eGFP positive PHK cells per genotype (control
vector, 5E7 or 16E7) for each infection set.
(TIF)
Figure S2 GST-E7 pull-down experiments. A) Immuno-
blots of purified GST and GST-E7Flag fusion proteins using an
anti-FLAG antibody. B) Ponceau red staining of GST fusion
proteins used as input for in vitro binding assays. C) GST fusion
proteins were immobilized and incubated with total protein
extracts of human HaCaT keratinocytes. Immunoblotting with
pRb and GST specific antibodies showed that E7 proteins from
HPV10, HPV5 and HPV16 interact with pRb. One tenth of the
total cell extract used in the GST pull-down assay (input) was also
analyzed. D) GST fusion proteins were immobilized and
incubated with purified His-pRb. Immunoblotting with pRb, His
and GST specific antibodies revealed that E7 proteins from
HPV10, HPV5 and HPV16 interact with purified pRb.
(TIF)
Figure S3 Stable transgene expression of E7 and eGFP
genes in PHKs and skin grafts. A) qRT-PCR analysis of
eGFP, 5E7 and 16E7 genes in transduced PHKs before grafting or
after the transplantation time. Shown are log2-based, z-values of
expression relative to housekeeping GUSB in PHK cells and
transplants (Materials and Methods). Horizontal lines represent
means for each sample group. V: control vector; 5: 5E7; 16: 16E7.
Normal macroscopic (B) or green fluorescence visualization (C) in
grafts is due to the expression of the eGFP transgene.
(TIF)
Figure S4 Pocket protein mRNA quantified in foreskin
PHKs. qRT-PCR was conducted for pRb, p107 and p130 genes
obtained from retrovirally transduced PHKs. Shown are log2-
based, z-values of expression relative to housekeeping GUSB in
PHK cells and transplants (Materials and Methods). Each dot
represents an individual sample. Horizontal lines represent means
for each sample group. No reduction in mRNA levels of
retinoblastoma family genes was observed upon E7 expression.
V: control vector; 5: 5E7; 16: 16E7. No significant gene expression
differences were detected between the samples as assessed by a
Student’s t-test (threshold p-val,0.05).
(TIF)
Figure S5 Immunostaining with anti-eGFP. Patchy ex-
pression was observed in the grafts corresponding to the control
vector, 5E7 and 16E7 samples. H&E staining of similar areas is
also shown.
(TIF)
Figure S6 Dermatoscopic images of human skin E7-
grafts. Representative images of control vector, 5E7, and 16E7
samples. Lower, right panel of 16E7 represents the highlighted
area in the left 16E7 image. Similar features to human viral warts
included: i) hyperkeratosis and papillomatosis (areas within dashed
lines), ii) capillaries (black arrows, and upper insert) and iii) crypts
associated with papillomatosis (white arrows and lower insert).
(TIF)
Figure 9. RNA expression quantification of oncogenic HPV biomarker genes and miRNAs. mRNA quantification of E2F1, CENPF, MELK and
RFC4 genes was conducted by qRT-PCR using RNA purified from PHK cells or grafts, or obtained from reported microarray experiments for CC or VIN.
Each dot represents an individual sample. Horizontal lines represent mean values in each sample group. (A) All genes were induced in E7-transduced
PHKs, though not significantly (Student’s t-test threshold p-val,0.05). Significant overexpression was also observed for all genes in HPV16 E7-
transplants, but only for E2F1 in HPV5 E7. Shown are log2-based, z-values of expression relative to housekeeping GUSB in PHK cells and transplants
(Materials and Methods). (B) Microarray expression patterns of each gene in CC and VIN infected with HR-HPVs are shown as log2-based, z-values
(Materials and Methods). All genes display significant overexpression in CC with respect to cervix uteri (N), and in VIN with respect to normal vulva (N).
Horizontal lines represent mean values in each sample group. *: p-val ,0.05, **: p-val ,0.005, ***: p-val ,0.0005, ****: p-val ,0.00005. V: control
vector; 5: HPV5 E7; 16: HPV16 E7. (C) miRNA was quantified by qRT-PCR for miR-146a, miR-21 and miR-200a, using RNA purified from skin grafts.
Shown are log2-based, z-values of expression relative to housekeeping U6B. Each dot represents an individual sample value. All miRNAs were
overexpressed in HPV16 E7-grafts. Only miR-21 displayed significant deregulation in transplants expressing HPV5 E7. Horizontal lines represent mean
values in each sample group. *: p-val ,0.05, **: p-val ,0.005, ***: p-val ,0.0005, ****: p-val ,0.00005. V: control vector; 5: HPV5 E7; 16: HPV16 E7.
doi:10.1371/journal.pone.0041743.g009
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Figure S7 Quantification of p21 mRNA expression. qRT-
PCR was conducted on p21, showing a moderate increase in PHK
cells before grafting that was significantly augmented after
transplantation in the case of HPV16 E7. Each dot represents
an individual sample. Horizontal lines represent means for each
sample group. Shown are log2-based, z-values of expression
relative to housekeeping GUSB in PHK cells and transplants
(Materials and Methods). V: control vector; 5: 5E7; 16: 16E7. A
Student’s t-test detected significant differences in gene expression
between the different samples (threshold p-val,0.05). ****: p-
val,0.00005.
(TIF)
Figure S8 HPV biomarker analysis in human infected
anogenital neoplasias. A) Immunohistochemistry of p16 using
the CINtec Histology Kit on skin E7-grafts and cervical carcinoma
samples. No differences were observed in transplants upon E7
expression. As expected, a CC sample was stained with the p16
antibody. PCNA and MCM7 expression patterns in clinical
samples of cervical intraepithelial neoplasia (B) and high grade
bowenoid papulosis (C). Dashed lines in C represent the basal
membrane.
(TIF)
Figure S9 qRT-PCR for miR-148a, miR-145 and miR-
203 miRNAs in E7-transplants. Each dot represents an
individual sample. Horizontal lines represent means for each
sample group. Shown are log2-based, z-values of expression
relative to housekeeping U6B (Materials and Methods). V: control
vector; 5: 5E7; 16: 16E7. A Student’s t-test was performed to
detect significant differences in gene expression between the
different samples (threshold p-val,0.05). No significant deregula-
tion was observed.
(TIF)
Table S1 Oligonucleotides used.
(XLS)
Table S2 Antibodies used.
(XLS)
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